Research progress on pharmacokinetics factors of warfarin

Abstract

Abstract:

Warfarin is the most frequently used oral anticoagulants, but most literatures of it focused on the safety and clinical dosages design due to its narrow therapeutic window. The various prediction formulae of clinical dose-adjustment of warfarin can only interpreter 40%-60% individualized difference of warfarin. This article reviews literatures about the factors influencing pharmacokinetics of warfarin and its potential drug interactions so as to provide referential evidences for the rational application of warfarin into clinic.

Key words: warfarin, pharmacokinetics, drug interaction

CLC Number:

R969.1

LI Haigang, FAN Rong, MA Ning, TANG Jing, LIAO Hongchun, ZHENG Xiahui. Research progress on pharmacokinetics factors of warfarin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1292-1298.

References

［1］Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments［J］. Lancet, 2015, 386(9990): 281-291.
［2］Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing［J］. Clin Pharmacol Ther, 2011, 90(4): 625-629.
［3］Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting［J］. Blood, 2009, 113(4): 784-792.
［4］Verhoef TI, Redekop WK, Daly AK, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon［J］. Br J Clin Pharmacol, 2014, 77(4): 626-641.
［5］Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation［J］. Circulation, 2007, 116(22): 2563-2570.
［6］Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives［J］. Thromb Res,2007, 120(1): 1-10.
［7］刘会臣. 手性药物的药代动力学立体选择性及其影响因素研究进展［J］. 中国临床药理学杂志, 2003,8(5): 380-383.
［8］李琳，张炜，沈陈林，等. 阿司匹林与华法林在体肠吸收的相互作用研究［J］. 中国临床药理学与治疗学, 2015,20(5): 486-492.
［9］Shen C, Huang X, Li J, et al. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs［J］. Xenobiotica, 2016, 46(6): 530-541.
［10］黄晓晖，王夏芹，唐海沁，等. 华法林和阿司匹林联用在大鼠体内的药代动力学研究(英文)［J］. 中国临床药理学与治疗学, 2012,17(2): 189-195.
［11］Niopas I, Toon S, Aarons L, et al. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans［J］. Eur J Clin Pharmacol, 1999, 55(5): 399-404.
［12］Impellizzeri P, Centonze A, Antonuccio P, et al. Utility of a scoring system in the diagnosis of acute appendicitis in pediatric age. A retrospective study［J］. Minerva Chir, 2002, 57(3): 341-346.
［13］Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research［J］. Pharmacogenomics J, 2007, 7(3): 154-179.
［14］De Oliveira AV, De Souza FA, Ribeiro DD, et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients［J］. J Thromb Haemost, 2011, 9(10): 2120-2122.
［15］Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors［J］. Pharmacogenomics J, 2004, 4(1): 40-48.
［16］Chai GH, Hu FQ, Sun J, et al. Transport pathways of solid lipid nanoparticles across Madin-Darby canine kidney epithelial cell monolayer［J］. Mol Pharm, 2014, 11(10): 3716-3726.
［17］Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose［J］? Circulation, 2014, 130(22): e191-e193.
［18］Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors［J］. Clin Pharmacokinet, 2002, 41(5): 343-370.
［19］Ermer JC, Hicks DR, Wheeler SC, et al. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin［J］. Clin Pharmacol Ther, 1994, 55(3): 305-316.
［20］Toon S, Trager WF. Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone［J］. J Pharm Sci, 1984, 73(11): 1671-1673.
［21］Lewis RJ, Trager WF. Warfarin metabolism in man: identification of metabolites in urine［J］. J Clin Invest, 1970, 49(5): 907-913.
［22］Lewis RJ, Trager WF, Robinson AJ, et al. Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols［J］. J Lab Clin Med, 1973, 81(6): 925-931.
［23］Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives［J］. Bioorg Med Chem, 2007, 15(6): 2414-2420.
［24］Jones DR, Miller GP. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know［J］. Expert Opin Drug Metab Toxicol, 2011, 7(7): 857-874.
［25］Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes［J］. Pharmacogenetics, 1998, 8(5): 365-373.
［26］Jones DR, Kim SY, Boysen G, et al. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin［J］. Drug Metab Lett, 2010, 4(4): 213-219.
［27］Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe［J］. Mol Pharmacol,1993, 43(2): 234-239.
［28］Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions［J］. Chem Res Toxicol, 1992, 5(1): 54-59.
［29］Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe［J］. Drug Metab Dispos, 1995, 23(12): 1339-1346.
［30］Miller GP. Warfarin therapy: how the less interesting half just got interesting［J］. J Thromb Haemost, 2010, 8(12): 2705-2707.
［31］Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions［J］. Chem Biol Interact, 2000, 129(1/2): 171-193.
［32］Zielinska A, Lichti CF, Bratton S, et al. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases［J］. J Pharmacol Exp Ther, 2008, 324(1): 139-148.
［33］Miller GP, Jones DR, Sullivan SZ, et al. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans［J］. Chem Res Toxicol,2009, 22(7): 1239-1245.
［34］Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions［J］. Arch Intern Med, 2005, 165(10): 1095-1106.
［35］Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature［J］. Pharmacotherapy, 2004, 24(2): 285-290.
［36］Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update［J］. J Thromb Thrombolysis, 2011, 31(3): 326-343.
［37］Dionisio D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine［J］. AIDS, 2001, 15(2): 277-278.
［38］陈刚，杨劲，张广钦. 华法林与胺碘酮相互作用研究进展［J］. 中国临床药理学与治疗学, 2017,22(2): 215-221.
［39］Lim MK, Sadarangani P, Chan HL, et al. Complementary and alternative medicine use in multiracial Singapore［J］. Complement Ther Med, 2005, 13(1): 16-24.
［40］Cuzzolin L, Francini-Pesenti F, Zaffani S, et al. Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study［J］. Pharmacoepidemiol Drug Saf, 2007, 16(9): 1014-1017.
［41］Ramsay NA, Kenny MW, Davies G, et al. Complimentary and alternative medicine use among patients starting warfarin［J］. Br J Haematol, 2005, 130(5): 777-780.
［42］Wong RS, Cheng G, Chan TY. Use of herbal medicines by patients receiving warfarin［J］. Drug Saf, 2003, 26(8): 585-588.
［43］Wang Z, Roberts JM, Grant PG, et al. The effect of a medicinal Chinese herb on platelet function［J］. Thromb Haemost, 1982, 48(3): 301-306.
［44］Wu WW, Yeung JH. Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo［J］. Phytomedicine, 2010, 17(3/4): 219-226.
［45］Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity［J］. Life Sci, 2002, 71(13): 1579-1589.
［46］Liu Y, Zhang JW, Li W, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes［J］. Toxicol Sci, 2006, 91(2): 356-364.
［47］Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans［J］. Clin Pharmacol Ther, 2002, 72(3): 276-287.
［48］Kent UM, Aviram M, Rosenblat M, et al. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9［J］. Drug Metab Dispos, 2002, 30(6): 709-715.
［49］Coderre K, Faria C, Dyer E. Probable warfarin interaction with menthol cough drops［J］. Pharmacotherapy, 2010, 30(1): 110.
［50］Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo［J］. Clin Pharmacol Ther, 2002, 72(3): 247-255.
［51］Mohammed AM, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects［J］. Br J Pharmacol, 2008, 154(8): 1691-1700.
［52］Booth SL, Madabushi HT, Davidson KW, et al. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone)［J］. J Am Diet Assoc, 1995, 95(1): 82-83.
［53］Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals［J］. Integr Cancer Ther, 2009, 8(3): 208-227.
［54］Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations［J］. Clin Pharmacol Ther, 1986, 39(1): 15-24.
［55］Zhou L, Wang S, Zhang Z, et al. Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin［J］. J Ethnopharmacol, 2012, 143(2): 648-655.
［56］程娟，李俊，宋珏，等. A771726在大鼠体内肝肠循环的研究［J］. 安徽医科大学学报, 2010,56 (3): 338-341.
［57］Li H, Wang Y, Fan R, et al. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage［J］. Drug Des Devel Ther, 2016, 10: 2173-2180.
［58］Li H, Zhang C, Fan R, et al. The effects of Chuanxiong on the pharmacokinetics of warfarin in rats after biliary drainage［J］. J Ethnopharmacol, 2016, 193: 117-124.
［59］Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action［J］. Arch Intern Med, 2007, 167(13): 1414-1419.
［60］Beyth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking coumarins［J］. Curr Hematol Rep, 2002, 1(1): 41-49.
［61］Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages［J］. Am J Med, 2007, 120(8): 700-705.
［62］Liu J, Jiang HH, Wu DK, et al. Effect of gene polymorphims on the warfarin treatment at initial stage［J］. Pharmacogenomics J, 2017, 17(1):47-52.
［63］Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy［J］. J Am Coll Cardiol, 2003, 41(9): 1633-1652.
［64］Wittkowsky AK. Factors associated with INR elevation and bleeding complications during Warfarin therapy［J］. Arch Intern Med, 2005, 165(6): 703.
［65］Marcatto LR, Sacilotto L, Darrieux FC, et al. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation［J］. Oncotarget, 2016, 7(34):54194-54199.
［66］Moreau C, Bajolle F, Siguret V, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement［J］. Blood, 2012, 119(3): 861-867.
［67］Self TH, Wallace JL, Sakaan S, et al. Effect of body weight on dose of vitamin K antagonists［J］. South Med J, 2015, 108(10): 637-643.
［68］Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data［J］. N Engl J Med, 2009, 360(8): 753-764.
［69］Pirmohamed M, Kamali F, Daly AK, et al. Oral anticoagulation: a critique of recent advances and controversies［J］. Trends Pharmacol Sci, 2015, 36(3): 153-163.
［70］Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose［J］. N Engl J Med, 2005, 352(22): 2285-2293.
［71］Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9［J］. Pharmacogenetics, 1994, 4(1): 39-42.
［72］Zhao Z, Moghadasian MH. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review［J］. Food Chem, 2008, 109(4): 691-702.
［73］Soucek P, Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms［J］. Xenobiotica, 1992, 22(1): 83-103.
［74］Tadros R, Shakib S. Warfarin--indications, risks and drug interactions［J］. Aust Fam Physician, 2010, 39(7): 476-479.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LIU Xiumei, GUO Qianqian, FANG Yuan, CHEN Nan, QI Qi. Pharmaceutical care of patients with antithrombotic therapy after transjugular intrahepatic portal shunt [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 556-560.
[6]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[7]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[10]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[11]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[12]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[13]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[14]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[15]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.